Oppenheimer Asset Management Inc. Buys 1,736 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Oppenheimer Asset Management Inc. grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report) by 12.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 15,929 shares of the company’s stock after purchasing an additional 1,736 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Neurocrine Biosciences were worth $1,792,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Acadian Asset Management LLC bought a new stake in shares of Neurocrine Biosciences during the first quarter worth $27,000. KB Financial Partners LLC acquired a new stake in shares of Neurocrine Biosciences in the first quarter valued at approximately $32,000. BluePath Capital Management LLC bought a new stake in shares of Neurocrine Biosciences in the third quarter worth $35,000. Covestor Ltd boosted its holdings in Neurocrine Biosciences by 431.0% during the first quarter. Covestor Ltd now owns 377 shares of the company’s stock worth $35,000 after purchasing an additional 306 shares during the last quarter. Finally, Bessemer Group Inc. grew its position in Neurocrine Biosciences by 755.0% in the fourth quarter. Bessemer Group Inc. now owns 342 shares of the company’s stock valued at $42,000 after purchasing an additional 302 shares in the last quarter. 93.54% of the stock is owned by institutional investors.

Insider Activity

In other news, Director William H. Rastetter sold 11,044 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $131.47, for a total value of $1,451,954.68. Following the completion of the transaction, the director now directly owns 51,741 shares in the company, valued at approximately $6,802,389.27. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director William H. Rastetter sold 11,044 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $131.47, for a total value of $1,451,954.68. Following the sale, the director now directly owns 51,741 shares in the company, valued at $6,802,389.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin Charles Gorman sold 105,835 shares of the firm’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $132.44, for a total transaction of $14,016,787.40. Following the transaction, the chief executive officer now owns 499,754 shares of the company’s stock, valued at approximately $66,187,419.76. The disclosure for this sale can be found here. In the last three months, insiders have sold 270,631 shares of company stock worth $35,043,864. Corporate insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Stock Performance

Shares of NBIX opened at $142.96 on Wednesday. Neurocrine Biosciences, Inc. has a 52-week low of $89.04 and a 52-week high of $143.35. The business’s fifty day moving average is $129.58 and its 200-day moving average is $116.49. The firm has a market cap of $14.05 billion, a price-to-earnings ratio of 76.86, a PEG ratio of 0.75 and a beta of 0.25.

Analyst Ratings Changes

NBIX has been the subject of a number of recent research reports. Stifel Nicolaus increased their price objective on shares of Neurocrine Biosciences from $141.00 to $144.00 and gave the stock a “buy” rating in a research note on Monday, December 18th. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 19th. Citigroup initiated coverage on shares of Neurocrine Biosciences in a research note on Wednesday, December 13th. They set a “neutral” rating and a $127.00 price objective on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $150.00 price target on shares of Neurocrine Biosciences in a report on Thursday, December 7th. Finally, The Goldman Sachs Group boosted their price target on Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. Six analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $134.69.

Check Out Our Latest Research Report on NBIX

Neurocrine Biosciences Profile

(Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

Further Reading

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.